Fever clearance time – subgroup analyses.

<p>Heterogeneity was tested with a Cox regression model that included an interaction between treatment effect and subgroup.</p><p>MIC's and age were missing for some patients. N number, pts patients, MIC minimum inhibitory concentration.</p

Trial profile.

<p>Numbers in blue font represent numbers of patients infected with nalidixic acid resistant isolates.</p

Treatment failure – subgroup analyses.

<p>Heterogeneity was tested with a Cox regression model that included an interaction between treatment effect and subgroup.</p>#<p>Based on Cox regression with Firth's penalized likelihood to cope with separation.</p><p>MIC's and age were missing for some patients. N number, pts patients, MIC minimum inhibitory concentration.</p

Minimum inhibitory concentration MIC of <i>Salmonella</i> Typhi and paratyphi A.

<p>132 <i>S</i>.Typhi and 86 <i>S</i>.Paratyphi A were available for MIC testing. MIC 50/90 = concentration at which 50% and 90% of the organisms, respectively, are inhibited. Comparison based on Fisher's exact test for categorical data and Wilcoxon test for continuous data.</p

Kaplan-Meier estimates for patients infected with nalidixic acid resistant isolates.

<p>Kaplan- Meier estimates of the probability of treatment failure, fever clearance time, and the probability of relapse for patients infected with nalidixic acid resistant isolates.</p

Baseline characteristics of patients according to treatment group (intention to treat population).

<p>AST = serum aspartate aminotransferase (normal range 12–30 U/L), ALT = serum alanine aminotransferase (normal range 13–40 U/L).</p

Scatter plots of drugs MIC versus fever clearance time.

<p>Gatifloxacin and ofloxacin MICs versus fever clearance time by treatment group for patients with blood culture confirmed enteric fever. Blue lines correspond to LOESS scatter plot smoothers.</p